To provide more robust evidence for clinicians, investigators analyzed the efficacy and safety of biologics in patients with lupus nephritis using meta-regression analyses that adjusted for trials’ ...

PTC518 was granted Fast Track designation based off strong 12-month interim data on safety and efficacy.

Adoption of DOAC population management tool dashboard before July 2018 linked to decline in off-label dosing prescriptions.

According to more recent data, it has been determined that Pemgarda is likely to retain adequate neutralization activity against KP.3.1.1. The Food and Drug Administration (FDA) has updated the Fact ...

Obinutuzumab, a monoclonal antibody that targets the CD20 receptor on B-cells, is currently indicated for the treatment of chronic lymphocytic leukemia and follicular lymphoma in combination with ...

HealthDay News — For patients with obesity, the addition of semaglutide to standard hidradenitis suppurativa (HS) treatments yields improvement in quality of life and a reduction in flares, according ...

Interest in vaccination is even lower this season than last, in which less than half (45%) of adults got a flu vaccine, according to CDC data.

The Orphan Drug designation is supported by positive preclinical data from bleomycin-induced mouse models and patient-derived skin fibroblasts.

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo.

In the TEMPO-1 trial, participants with early PD were randomly assigned to receive tavapadon 5mg or 15mg once daily or placebo.

The Infectious Diseases Society of America aimed to develop up-to-date guidance focusing on the treatment of antimicrobial-resistant gram-negative infections.

Pfizer has made the decision to withdraw Oxbryta (voxelotor), a treatment for sickle cell disease, from all markets where it is approved. Additionally, all clinical trials evaluating voxelotor, as ...